SCHEMBL8649003

SCHEMBL8649003

Oc1cc2cc[nH]c2cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 1/20 0.60
AHR P35869 6/20 0.50
MAOB P27338 4/20 0.50
MAOA P21397 3/20 0.50
NR4A2 P43354 2/20 0.50
CMA1 P23946 1/20 0.50
F7 P08709 1/20 0.50
LTA4H P09960 1/20 0.50
F3 P13726 1/20 0.50
TYR P14679 1/20 0.50
USP2 O75604 1/20 0.50
GAA P10253 1/20 0.50
ALOX15 P16050 1/20 0.50
RAD51 Q06609 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GPR84 Q9NQS5 1/20 0.47
ENPP2 Q13822 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613747 0.82 CSNK2A1 (0.69) CSNK2A1AHRMAOBMAOANR4A2
SCHEMBL48994 0.82 TYR (0.58) CSNK2A1AHRNR4A2CMA1F7
SCHEMBL31375351 0.82 TYR (0.58) CSNK2A1AHRNR4A2CMA1F7
SCHEMBL28298713 0.82 TYR (0.58) CSNK2A1AHRNR4A2CMA1F7
SCHEMBL31375356 0.82 TYR (0.58) CSNK2A1AHRNR4A2CMA1F7
Ethoxycarbonyl Group SCHEMBL27768302 0.81 CSNK2A1 (0.42) CSNK2A1AHRMAOBMAOANR4A2
Hydrochloric Acid SCHEMBL4625112 0.80 TYR (0.56) CSNK2A1AHRNR4A2CMA1F7
Bromide SCHEMBL27546379 0.80 TYR (0.56) CSNK2A1AHRNR4A2CMA1F7
Bromide SCHEMBL29769307 0.80 TYR (0.56) CSNK2A1AHRNR4A2CMA1F7
SCHEMBL1401662 0.75 GPR84 (0.69) CSNK2A1AHRNR4A2CMA1F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024220852-A2 TEAD CORE INHIBITORS FOR CANCER THERAPEUTICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-10-24 WO disclosed
EP-2960238-B1 MONOCYCLIC PYRIDINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 EP disclosed
EP-2960238-B1 MONOCYCLIC PYRIDINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 EP disclosed
EP-2960238-A1 MONOCYCLIC PYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2015-12-30 EP disclosed
EP-2960238-A1 MONOCYCLIC PYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2015-12-30 EP disclosed
WO-2014129477-A1 MONOCYCLIC PYRIDINE DERIVATIVE エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) 2014-08-28 WO disclosed
US-5736534-A HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA PFIZER INC. (US) 1998-04-07 US disclosed
CN-1141633-A 4-heterocyclic substituted quinazoline derivatives, process for their preparation and their use as anticancer agents PFIZER (US) 1997-01-29 CN disclosed
EP-0746554-A1 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS PFIZER INC. (US) 1996-12-11 EP disclosed
WO-1995023141-A1 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS PFIZER INC. (US) 1995-08-31 WO disclosed